Marketresearchnews

Tuesday, 25 May 2021

Whipple’s disease Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

Market Scenario:

Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially, the small intestine. The infection may spread to any part of the body but mostly it affects the central nervous system, joints, lungs, heart, and eyes. Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms. The prevalence is one in one million people. The prevalence of this diseases is more in men than women.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4094

Ongoing research and clinical trial to find effective cure drive the growth of market. Advancement in medical technology and increasing awareness about this disease boost the market growth.

The global Whipple’s disease market is expected to grow at the CAGR of ~3.1% during the forecast period and is estimated to reach USD 255.3 million by 2023.

Key Players in the Global Whipple’s Disease Market

Some of the key players in this market: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)

Segments

The global Whipple’s disease market is segmented on the basis of diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others. Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others. Blood tests sub-segmented into Complete blood count (CBC), Red Blood Cell Count (RBC), serum albumin test, total protein test, and others.

On the basis of treatments, the market is segmented into medications, supplements, and others. Medications is sub-segmented into Intravenous (IV) ceftriaxone (Rocephin), Intravenous (IV) penicillin, sulfamethoxazole-trimethoprim, SMX-TMP, oxycycline (Vibramycin), hydroxychloroquine (Plaquenil), and others. Supplements include vitamin supplements, mineral supplements, and others.

On the basis of end user, it is segmented into hospitals & clinics, academic institutes, medical research centers, and others.

Regional Analysis of the Global Whipple’s Disease Market

The Americas holds the largest share in the global Whipple’s disease market. North American region, especially, the US dominates the market in this region. It is a rare disease and found in around less than one in million people in US. Some other factors such as advanced medical facilities, ongoing research and clinical trials, and availability of skilled health professionals. Increasing awareness about this disease in Latin America drives market growth in this region.

The new cases of this disease is increasing in Europe. Availability of advanced diagnostic and therapeutic options, high awareness among the European population, and availability of skilled medical professional drive the European market. Availability of cost-effective of treatment in East European countries, for instance, Poland than the other parts of the region add fuel to the growing demand. Owing to availability of cost-effective treatment, patients from Western European countries and Russia travel to East and Central European countries to treat this disease.

Asia Pacific region shows low prevalence of the disease. Increasing awareness about this disease in the Asian population leads the market growth. The rapidly developing healthcare sector is another major driver of the market. Due to rapid economic growth, rising middle class population, and their spending on healthcare and related services add fuel to the growth of this market.

Owing to lack of awareness about the disease, slow healthcare infrastructure development, and limited access to required medical facilities, the Middle East & Africa market is growing slower as compared to the global average. On the other hand, due to developed healthcare facilities and government support to improve public health, the Middle East countries such as the UAE dominates market of this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/whipple-s-disease-market-4094

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Leprosy Treatment Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Market scenario:

Leprosy is a chronic infection caused by the bacteria Mycobacterium leprae or Mycobacterium lepromatosis causing granulomas of the nerves, respiratory tract etc. The granulomas may result in lack of ability to feel pain, especially in the extremities such as finger tips. The global market for leprosy is falling due to early detection and awareness campaigns and integration of basic leprosy services into general health services of many countries.

Considering all these factors the leprosy treatment market size is expected to reach $ 3.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/3862

Key players

Glaxo Smithcline
Systopic Laboratories Pvt. Ltd.
Cadila Pharmaceuticals
Acme Pharmaceuticals
Macleods Pharmaceuticals
Novartis International AG
Astra Zeneca
Lark Laboratories Ltd.

Segments:

The global leprosy treatment market is segmented on the basis of drug class, disease type and market channel. Based on drug class, the market has been segmented as sulfone, phenazine, derivative, anti-tubercular drugs and others. Based on the disease type, the market has been segmented as paucibacillary leprosy, multibacillary leprosy. Based on the end users, the market has been segmented as private, contract and others.

Regional analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global leprosy treatment. Europe is the second largest market due to large disposable income and rising awareness. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.Asia Pacific region is expected to have the most potential and it is estimated to be led by China and India.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/leprosy-treatment-market-3862

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Big Data in Healthcare Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

Market Overview

Market Research Future (MRFR) believes that upcoming Big Data in Healthcare Market trends holds a lot of promise and can escalate at a stunning rate between 2018 and 2023 (analysis period).

COVID-19 Analysis

While various industries are dealing with huge losses following the COVID-19 outbreak and the subsequent lockdown, big data in healthcare market has remained strong and shown steady growth. A number of healthcare providers and facilities are increasingly adopting big data to review the SARS-CoV-2 pandemic situation as well as its economic impact.

Many of the big data firms are collaborating with several government agencies, industries and research organizations to given them access to advanced AI tools. They are also forming alliance with data and public health professionals to combat the novel coronavirus. Additionally, renowned pharmaceutical vendors are performing clinical trials with respect to SARS-CoV-2, wherein big data has been an important component as it helps quickly transfer insightful clinical data.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/948

Market Dynamics

Drivers

Staggering Growth in Unstructured Medical Data to Foster Demand

Advances in metabolomics, epigenomics, proteomics, genomics, pharmacogenomics and transcriptomics have been responsible for significant generation of unstructured medical data. The escalating role of data analytics and big data in healthcare to develop predictive models has opened exciting new frontiers, in terms of market growth.

Over the years, encouraged by data mining techniques along with the innovations in healthcare IT, the big data in healthcare market has managed to take massive strides across the globe. Also, the expanding use cases of big data in multiple biosciences applications, particularly in genomic sequencing and drug discovery have promoted market growth. Besides this, the rising availability of cost effective big data services and software has boosted their demand in the healthcare industry.

Opportunities

Surging Adoption of the Cloud Model Presents Lucrative Opportunities to Players

Cloud storage has emerged as a popular model in healthcare, as it helps lower the costs and is highly reliable. Nearly 90 percent of global healthcare vendors are making use of cloud-based big data analytics, including applications and storage, as these provide faster disaster recovery, and smoother expansion. In a nutshell, the rising popularity of cloud storage can emerge as a lucrative opportunity for the leading competitors in the global market.

Restraints

Huge Investments Required for Implementing Big Data to be a Huge Restraint

Substantial venture capital investments required for implementation of big data in healthcare could restrain the market’s growth rate in the following years.

Challenges

Data Privacy Issues& Security Concerns to Challenge Adoption Rate

Data privacy issues as well as security concerns arising with the rising use of big data in healthcare can be a huge challenge in the coming years. Even an extremely secure data center can face issues due to human error, giving way to unethical hackers trying to gain access to sensitive and high-value data.

Segment Overview

Firewalls Segment to Seize the Biggest Share

The top hardware-based segments are firewalls, routers, data storage, email servers, access points and VPNs. Rapidly growing sophistication level of cyber-attacks in healthcare has created a massive demand for advanced firewall hardware, which means that the firewalls segment can secure the leading spot in the global market.

EHR Software to Nab the Top Position

Software-wise, the market segments are EHR, practice management, workforce management and revenue cycle management. The heightened need to centralize and streamline electronic healthcare systems, technological innovations and rising awareness regarding the important as well as use of EHR can ensure the segmental growth in the coming years.

Predictive Analytical Service Type to Enjoy Robust Demand

The key analytical service types considered are predictive, prescriptive and descriptive. Predictive analytics in healthcare help achieve practical goals with its ability to predict future events, and it is widely used in areas like financial management, operations management, clinical and population health management applications. As a result, MRFR expects the predictive analytical service type to dominate the global industry during the evaluation timeline.

Clinical Data Analytics to Gain Highest Impetus

Top applications of big data in healthcare include financial analytics, operational analytics and clinical data analytics. The clinical data analytics market has covered substantial grounds in the past few years, owing to the rise in favorable regulations, surging pressure to cut down the costs associated with drug development, and growing need for new therapies. Clinical data analytics in healthcare helps cure and predict diseases, thereby boosting the quality of healthcare and facilitating preventable deaths, which can take place owing to negligence.

Regional Analysis

North America Big Data Analytics in Healthcare Market takes the Lead

North America has been one of the earliest regions to embrace digitization, especially the healthcare industry, which generates colossal volumes of raw unorganized data. The region has been leveraging the host of benefits of big data in healthcare, while rapidly adopting AI and IoT. The demand for big data analytics for population health management has elevated considerably over the years, plus the emerging eHealth trend also bolsters the market position. Another significant trend in the region has been the growing preference for a value-based care model over the pay-for-service model, which takes into consideration the patient’s treatment success rate instead of rewarding the healthcare workers for merely performing the procedure.

The European Market to be the Second Biggest Gainer

The European market is the second-highest gainer, thanks to the importance given to the role of data analytics and big data in healthcare and the high expenditure in this regard. Surge in extensive research and development activities backed by the strong government support combined with the accelerated use of smart connected devices are responsible for market growth in the region. Rising prevalence of digitization is prompting healthcare vendors to adopt big data solutions, with the key focus on reducing clinical errors. A fast emerging segment in the market has been sentiment analysis using big data in healthcare industry, given the soaring number of pharmaceutical firms in Europe with massive volumes of unstructured data, from which they aim to achieve useful insights.

Asia Pacific – Adoption of Big Data and Analytics in Mobile Healthcare Market: An Economic Perspective

Asia Pacific is the fastest emerging market, accounting for 41% of the total share. Big data analytics has been a major hit in the mobile healthcare market, leading to considerable profits owing to the escalating internet and smart phone use. Furthermore, the region has witnessed a striking growth in the adoption of wearable devices and mobile health applications, which has created a huge demand for big data in the healthcare industry.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/global-big-data-healthcare-market-948

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Retinal Detachment Market Is Seeing Explosive Growth by Future Industry Winners: Forecast, 2020-2027

Market Scenario:

Retinal Detachment Market research expected to exhibit significant growth over the forecast period. The market is projected to register a CAGR of 6.2% over the forecast period and is estimated to reach USD 2,892.5 Million by 2025.

Retinal detachment is a critical situation of the eye wherein a thin layer of tissue (the retina) at the back of the eye pulls away from its normal position. This condition separates the retinal cells from the layer of blood vessels that provides oxygen and nourishment to the eyes.

Factors such as the rising cases of retinal detachment and growing technological advancements are expected to drive the market growth. Furthermore, the rise in the number of eye surgeries is also expected to drive the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1640

However, the high price of retinal surgery instruments, limited availability of skilled professionals, and lack of awareness in the developing economies are expected to hamper the market growth.

Segmentation

The Global Retinal Detachment Market has been segmented into Condition Type, Treatment, End User, and Region.

Based on condition type, the global retinal detachment market has been divided into rhegmatogenous retinal detachment, tractional retinal detachment, and exudative retinal detachment.

The global retinal detachment market, by treatment, has been segmented into photocoagulation (laser surgery), cryopexy (freezing), pneumatic retinopexy, scleral buckling, and vitrectomy.

The global retinal detachment market, by end-user, has been segmented into hospitals & clinics, specialty centers, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The retinal detachment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European retinal detachment market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified into France, Germany, Spain, the UK, Italy, and the rest of Western Europe.

The retinal detachment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

The Middle East & Africa retinal detachment market has been segmented into the Middle East and Africa.

Key Players

Carl Zeiss Meditec AG (Germany), Meridian AG (Switzerland), IRIDEX Corporation (US), Ellex Medical Lasers Ltd (Australia), FCI (US), Millennium Surgical Corp. (US), BVM Medical Limited (UK), Lombart Instrument, Inc. (US), and Welch Allyn (US) are some of the key players operating in the global retinal detachment market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/retinal-detachment-treatment-market-1640

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Monday, 24 May 2021

Chinese Fibromyalgia Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used. Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5630

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others

Chinese fibromyalgia industry is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.

Intended Audience

Pharmaceutical Companies
Hospitals & Clinics
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Key Findings

The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Dravet syndrome Market Organization Sizes Analysis 2020-2027

Market Scenario:

Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.

It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5509

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.

Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.

It is estimated that the Dravet syndrome treatment industry is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.

Intended Audience:

Pharmaceutical Companies
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities

Key Players:

Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.

Segmentation:

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.

On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Browse More Details of the Report @

@ https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hematocrit Test Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5553

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

The global hematocrit test devices market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

Medical Device Manufacturers
Medical Device Suppliers
Medical Research Laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors

Regional Analysis of the Global Hematocrit Test Market

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services. In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com